<SEC-DOCUMENT>0001140361-23-040773.txt : 20230821
<SEC-HEADER>0001140361-23-040773.hdr.sgml : 20230821
<ACCEPTANCE-DATETIME>20230821215820
ACCESSION NUMBER:		0001140361-23-040773
CONFORMED SUBMISSION TYPE:	144
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20230821
DATE AS OF CHANGE:		20230821

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Roivant Sciences Ltd.
		CENTRAL INDEX KEY:			0001635088
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				981173944
		STATE OF INCORPORATION:			D0
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		144
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	001-40782
		FILM NUMBER:		231190874

	BUSINESS ADDRESS:	
		STREET 1:		CLARENDON HOUSE, 2 CHURCH STREET
		CITY:			HAMILTON HM11
		STATE:			D0
		ZIP:			HM11
		BUSINESS PHONE:		441-295-5950

	MAIL ADDRESS:	
		STREET 1:		CLARENDON HOUSE
		STREET 2:		2 CHURCH STREET
		CITY:			HAMILTON
		STATE:			D0
		ZIP:			HM11

REPORTING-OWNER:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kumar Rakhi
		CENTRAL INDEX KEY:			0001856296

	FILING VALUES:
		FORM TYPE:		144

	MAIL ADDRESS:	
		STREET 1:		C/O NEUROPACE INC
		STREET 2:		455 N BERNARDO AVENUE
		CITY:			MOUNTAIN VIEW
		STATE:			CA
		ZIP:			94043
</SEC-HEADER>
<DOCUMENT>
<TYPE>144
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/ownership" xmlns:com="http://www.sec.gov/edgar/common">
<headerData>
<submissionType>144</submissionType>
<filerInfo>
<filer>
<filerCredentials>
<cik>0001856296</cik>
<ccc>XXXXXXXX</ccc>
</filerCredentials>
</filer>
<liveTestFlag>LIVE</liveTestFlag>



</filerInfo>
</headerData>
<formData>
<issuerInfo>
<issuerCik>0001635088</issuerCik>
<issuerName>Roivant Sciences Ltd.</issuerName>
<secFileNumber>001-40782</secFileNumber>
<issuerAddress>
<com:street1>7th Floor</com:street1>
<com:street2>50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</issuerAddress>
<issuerContactPhone>44 207 400 3347</issuerContactPhone>
<nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>Rakhi Kumar</nameOfPersonForWhoseAccountTheSecuritiesAreToBeSold>
<relationshipsToIssuer>
<relationshipToIssuer>Chief Accounting Officer</relationshipToIssuer>
</relationshipsToIssuer>
</issuerInfo>
<securitiesInformation>
<securitiesClassTitle>Common shares, $0.0000000341740141 par value per share (???Common Shares???)</securitiesClassTitle>
<brokerOrMarketmakerDetails>
<name>E*TRADE FINANCIAL CORPORATION</name>
<address>
<com:street1>3 EDISON DRIVE</com:street1>
<com:city>ALPHARETTA</com:city>
<com:stateOrCountry>GA</com:stateOrCountry>
<com:zipCode>30005</com:zipCode>
</address>
</brokerOrMarketmakerDetails>
<noOfUnitsSold>2674</noOfUnitsSold>
<aggregateMarketValue>29066.38</aggregateMarketValue>
<noOfUnitsOutstanding>771742197</noOfUnitsOutstanding>
<approxSaleDate>08/21/2023</approxSaleDate>
<securitiesExchangeName>NASDAQ</securitiesExchangeName>
</securitiesInformation>
<securitiesToBeSold>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<acquiredDate>08/20/2023</acquiredDate>
<natureOfAcquisitionTransaction>Restricted Stock Units granted under the Roivant Sciences Ltd. Amended and Restated 2015 Equity Incentive Plan</natureOfAcquisitionTransaction>
<nameOfPersonfromWhomAcquired>Roivant Sciences Ltd.</nameOfPersonfromWhomAcquired>
<isGiftTransaction>N</isGiftTransaction>
<amountOfSecuritiesAcquired>2674</amountOfSecuritiesAcquired>
<paymentDate>08/20/2023</paymentDate>
<natureOfPayment>N/A</natureOfPayment>
</securitiesToBeSold>
<nothingToReportFlagOnSecuritiesSoldInPast3Months>N</nothingToReportFlagOnSecuritiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>05/23/2023</saleDate>
<amountOfSecuritiesSold>1557</amountOfSecuritiesSold>
<grossProceeds>14916.06</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>06/09/2023</saleDate>
<amountOfSecuritiesSold>43893</amountOfSecuritiesSold>
<grossProceeds>435857.49</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>06/22/2023</saleDate>
<amountOfSecuritiesSold>1357</amountOfSecuritiesSold>
<grossProceeds>13583.57</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>07/14/2023</saleDate>
<amountOfSecuritiesSold>535</amountOfSecuritiesSold>
<grossProceeds>6420</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>07/18/2023</saleDate>
<amountOfSecuritiesSold>100</amountOfSecuritiesSold>
<grossProceeds>1200</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>07/24/2023</saleDate>
<amountOfSecuritiesSold>1393</amountOfSecuritiesSold>
<grossProceeds>15309.07</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>08/01/2023</saleDate>
<amountOfSecuritiesSold>336</amountOfSecuritiesSold>
<grossProceeds>4032</grossProceeds>
</securitiesSoldInPast3Months>
<securitiesSoldInPast3Months>
<sellerDetails>
<name>Rakhi Kumar</name>
<address>
<com:street1>c/o Roivant Sciences Ltd.</com:street1>
<com:street2>7th Floor, 50 Broadway</com:street2>
<com:city>London</com:city>
<com:stateOrCountry>X0</com:stateOrCountry>
<com:zipCode>SW1H 0DB</com:zipCode>
</address>
</sellerDetails>
<securitiesClassTitle>Common Shares</securitiesClassTitle>
<saleDate>08/03/2023</saleDate>
<amountOfSecuritiesSold>3681</amountOfSecuritiesSold>
<grossProceeds>44172</grossProceeds>
</securitiesSoldInPast3Months>
<remarks>The securities included in Table I represent a maximum number of shares that may be sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person are settled. The securities reported in Table I do not represent discretionary trades by the reporting person, and will be sold, or were sold, as applicable, for the limited purpose of satisfying tax withholding obligations. The securities included in Table II sold on May 23, 2023 and June 22, 2023 represent shares sold to cover the reporting person's tax obligations when restricted stock units belonging to the reporting person were settled. Table II does not include shares that were "net settled" by the Issuer in order to satisfy applicable tax withholding obligations in connection with the vesting and settlement of Restricted Stock Units previously granted to the reporting person.</remarks>
<noticeSignature>
<noticeDate>08/21/2023</noticeDate>
<planAdoptionDates>
<planAdoptionDate>02/17/2022</planAdoptionDate>
</planAdoptionDates>
<signature>/s/ Rakhi Kumar</signature>
</noticeSignature>
</formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
